These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
112 related articles for article (PubMed ID: 35864719)
1. Attention to risk information in direct-to-consumer prescription drug print ads: An eye-tracking study. Aikin KJ; Sullivan HW; Caporaso A; Hoverman V; Yan T; Williams D; Crafts J Pharmacoepidemiol Drug Saf; 2023 Mar; 32(3):312-320. PubMed ID: 35864719 [TBL] [Abstract][Full Text] [Related]
2. Effects of comparative claims in prescription drug direct-to-consumer advertising on consumer perceptions and recall. O'Donoghue AC; Williams PA; Sullivan HW; Boudewyns V; Squire C; Willoughby JF Soc Sci Med; 2014 Nov; 120():1-11. PubMed ID: 25194471 [TBL] [Abstract][Full Text] [Related]
3. Fair Balance and Adequate Provision in Direct-to-Consumer Prescription Drug Online Banner Advertisements: A Content Analysis. Adams C J Med Internet Res; 2016 Feb; 18(2):e33. PubMed ID: 26892749 [TBL] [Abstract][Full Text] [Related]
4. Using a drug facts box to communicate drug benefits and harms: two randomized trials. Schwartz LM; Woloshin S; Welch HG Ann Intern Med; 2009 Apr; 150(8):516-27. PubMed ID: 19221371 [TBL] [Abstract][Full Text] [Related]
5. Correction of misleading information in prescription drug television advertising: The roles of advertisement similarity and time delay. Aikin KJ; Southwell BG; Paquin RS; Rupert DJ; O'Donoghue AC; Betts KR; Lee PK Res Social Adm Pharm; 2017; 13(2):378-388. PubMed ID: 27178746 [TBL] [Abstract][Full Text] [Related]
6. Communicating efficacy information based on composite scores in direct-to-consumer prescription drug advertising. Williams PA; O'Donoghue AC; Sullivan HW; Willoughby JF; Squire C; Parvanta S; Betts KR Patient Educ Couns; 2016 Apr; 99(4):583-590. PubMed ID: 26589655 [TBL] [Abstract][Full Text] [Related]
7. Serious and actionable risks, plus disclosure: Investigating an alternative approach for presenting risk information in prescription drug television advertisements. Betts KR; Boudewyns V; Aikin KJ; Squire C; Dolina S; Hayes JJ; Southwell BG Res Social Adm Pharm; 2018 Oct; 14(10):951-963. PubMed ID: 28844621 [TBL] [Abstract][Full Text] [Related]
8. Content analysis of false and misleading claims in television advertising for prescription and nonprescription drugs. Faerber AE; Kreling DH J Gen Intern Med; 2014 Jan; 29(1):110-8. PubMed ID: 24030427 [TBL] [Abstract][Full Text] [Related]
9. Presenting efficacy information in direct-to-consumer prescription drug advertisements. O'Donoghue AC; Sullivan HW; Aikin KJ; Chowdhury D; Moultrie RR; Rupert DJ Patient Educ Couns; 2014 May; 95(2):271-80. PubMed ID: 24581929 [TBL] [Abstract][Full Text] [Related]
10. Consumer friendly or reader hostile? An evaluation of the readability of DTC print ads. Sheehan K Health Mark Q; 2008; 23(4):1-16. PubMed ID: 19042509 [TBL] [Abstract][Full Text] [Related]
11. Consumer responses to framing statements preceding the major risk statement in prescription drug DTC TV ads. Aikin KJ; Betts KR; Boudewyns V; Johnson M; Davis CN Res Social Adm Pharm; 2020 Sep; 16(9):1237-1247. PubMed ID: 31838056 [TBL] [Abstract][Full Text] [Related]
12. Disease Information in Direct-to-Consumer Prescription Drug Print Ads. Aikin KJ; Sullivan HW; Betts KR J Health Commun; 2016; 21(2):228-39. PubMed ID: 26717304 [TBL] [Abstract][Full Text] [Related]
13. Consumers' Understanding of FDA Approval Requirements and Composite Scores in Direct-to-Consumer Prescription Drug Print Ads. O'Donoghue AC; Sullivan HW; Williams PA; Squire C; Betts KR; Fitts Willoughby J; Parvanta S J Health Commun; 2016 Aug; 21(8):927-34. PubMed ID: 27414000 [TBL] [Abstract][Full Text] [Related]
14. Attention to and Distraction from Risk Information in Prescription Drug Advertising: An Eye Tracking Study. Sullivan H; Boudewyns V; O'Donoghue A; Marshall S; Williams PA J Public Policy Mark; 2017 Sep; 36(2):236-245. PubMed ID: 33505105 [TBL] [Abstract][Full Text] [Related]
15. Randomized trial of risk information formats in direct-to-consumer prescription drug advertisements. Aikin KJ; O'Donoghue AC; Swasy JL; Sullivan HW Med Decis Making; 2011; 31(6):E23-33. PubMed ID: 21690303 [TBL] [Abstract][Full Text] [Related]
16. The Effect of Including Quantitative Information on Multiple Endpoints in Direct-to-Consumer Prescription Drug Television Advertisements. Sullivan HW; O'Donoghue AC; Lynch M; Johnson M; Davis C; Rupert DJ Med Decis Making; 2019 Nov; 39(8):975-985. PubMed ID: 31583947 [No Abstract] [Full Text] [Related]
17. Now you see it. Now you don't: fair balance and adequate provision in advertisements for drugs before and after the switch from prescription to over-the-counter. Faerber AE; Kreling DH Health Commun; 2012; 27(1):66-74. PubMed ID: 21745037 [TBL] [Abstract][Full Text] [Related]
18. Randomized study of placebo and framing information in direct-to-consumer print advertisements for prescription drugs. O'Donoghue AC; Sullivan HW; Aikin KJ Ann Behav Med; 2014 Dec; 48(3):311-22. PubMed ID: 24682975 [TBL] [Abstract][Full Text] [Related]
19. Consumer tradeoff of advertising claim versus efficacy information in direct-to-consumer prescription drug ads. Aikin KJ; Betts KR; Ziemer KS; Keisler A Res Social Adm Pharm; 2019 Dec; 15(12):1484-1488. PubMed ID: 30846370 [TBL] [Abstract][Full Text] [Related]
20. Effects of conflicting prescription drug information from direct-to-consumer advertising and drug injury advertising on patients' beliefs and medication adherence. Im H; Huh J Res Social Adm Pharm; 2022 Jul; 18(7):3119-3130. PubMed ID: 34454872 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]